Official Title
ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer
Brief Summary

This expanded access protocol is designed to provide Recombinant Mycobacterium BCG(rMBCG) to patients with Non-muscle invasive bladder cancer (NMIBC) who are eligible toreceive TICE® BCG, may benefit from its use, and who are ineligible to participate in aclinical trial using rMBCG, or for other reasons cannot participate (eg, geographicallyunable to access a study site).

Detailed Description

Not Provided

Available
Treatment IND/Protocol
NMIBC

Biological: rMBCG

1-19.2e8 colony-forming units (CFU) of rMBCG

Eligibility Criteria

Inclusion Criteria:

Participants must meet all of the following criteria for inclusion in the study:

1. Age ≥18 years old.

2. Histologic confirmation of non-muscle invasive bladder cancer of the transitional
cell carcinoma high-grade subtype (mixed histology tumors allowed if transitional
cell histology is predominant histology).

3. Ineligible to participate in a clinical trial using rMBCG or geographically unable
to access a rMBCG clinical trial site.

4. Voluntary written informed consent and agreement to comply with all protocol
specified procedures and follow-up evaluations.

Exclusion Criteria:

Participants with any of the following criteria are excluded from participation in the
study:

1. Other illness or condition, including laboratory abnormalities, which in the opinion
of the Investigator would exclude the participant from participating in this study.
This includes, but is not limited to, serious medical conditions or psychiatric
illness likely to interfere with participation in the study.

2. Women who are pregnant or nursing. Female participants of childbearing potential
must have a negative pregnancy test and must adhere to using a medically acceptable
method of birth control prior to screening and agree to continue its use during the
study and for 30 days after the last dose of study drug, or be surgically sterilized
(eg, hysterectomy or tubal ligation). Women of childbearing potential are defined as
any female who has experienced menarche and who is NOT permanently sterile or
postmenopausal. Postmenopausal is defined as 12 consecutive months with no menses
without an alternative medical cause. Males must agree to use barrier methods of
birth control while on study and for 90 days post last dose of study drug.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 100 Years
Countries
United States
Locations

Urology Centers of Alabama
Homewood, Alabama, United States

University Urology
Mobile, Alabama, United States

Urology Associates
Mobile, Alabama, United States

Mayo Clinic
Phoenix, Arizona, United States

Center for Neurosciences
Tucson, Arizona, United States

UC San Diego Moores Cancer Center
La Jolla, California, United States

USC/ Norris Comprehensive Cancer Center
Los Angeles, California, United States

Urology Center of Southern California
Murrieta, California, United States

Saint John's Cancer Institute (Providence)
Santa Monica, California, United States

MedStar Washington Hospital Center
Washington D.C., District of Columbia, United States

Broward Urology Center
Fort Lauderdale, Florida, United States

Genesis Care
Fort Myers, Florida, United States

Mayo Clinic
Jacksonville, Florida, United States

Cohen Urology
Lake Worth, Florida, United States

Sebring Urology Center
Sebring, Florida, United States

Florida Urology Partners
Tampa, Florida, United States

Albany Urology Clinic and Surgery Center
Albany, Georgia, United States

Emory University
Atlanta, Georgia, United States

Georgia Urology
Atlanta, Georgia, United States

Augusta Urology Associates, LLC
Evans, Georgia, United States

Hawaii Cancer Care
Honolulu, Hawaii, United States

Island Urology Oahu
Honolulu, Hawaii, United States

North Idaho Urology, PLLC
Coeur d'Alene, Idaho, United States

The Urology Clinic
Meridian, Idaho, United States

Advanced Urology Skokie
Skokie, Illinois, United States

Urology of Indiana
Carmel, Indiana, United States

US Urology Partners - Carmel
Greenwood, Indiana, United States

First Urology, P.S.C
Jeffersonville, Indiana, United States

Kansas City Urology Care, PA
Lenexa, Kansas, United States

Wichita Urology
Wichita, Kansas, United States

Louisiana Healthcare Associates
Covington, Louisiana, United States

NRMC Urology Associates
Natchitoches, Louisiana, United States

Willis Knighton Urologic Oncology at Pierremont
Shreveport, Louisiana, United States

Pioneer Valley Urology, P.C.
Springfield, Massachusetts, United States

Karmanos Cancer Institute
Detroit, Michigan, United States

Comprehensive Urology
Waterford, Michigan, United States

Essentia Health - Duluth Clinic
Duluth, Minnesota, United States

Allina Health Cancer Institute- Abbott Northwestern Hospital
Minneapolis, Minnesota, United States

Minnesota Urology
Woodbury, Minnesota, United States

Cancer Partners of Nebraska
Lincoln, Nebraska, United States

The Urology Center, P. C. D/B/A/ UroHealth Partners
Omaha, Nebraska, United States

University Urology of NJ
Hamilton, New Jersey, United States

Advance Urology Associates Enterprises/ HLP Urology Associates
Manasquan, New Jersey, United States

Garden State Urology
Morristown, New Jersey, United States

Capital Health Urology
Pennington, New Jersey, United States

NYU Langone Health
New York, New York, United States

SUNY Upstate Medical University
Syracuse, New York, United States

Advanced Urology, Center for Robotic Surgery
Leland, North Carolina, United States

Cleveland Clinic
Garfield Heights, Ohio, United States

Department of Urology, Jefferson Einstein Hospital
Philadelphia, Pennsylvania, United States

Center for Urologic Care of Berks County
Wyomissing, Pennsylvania, United States

Urology Associates of Charleston
Mt. Pleasant, South Carolina, United States

AUC Urologists, LLC
Myrtle Beach, South Carolina, United States

Erlanger Health, Inc.
Chattanooga, Tennessee, United States

The West Clinic, PLLC dba West Cancer Center
Germantown, Tennessee, United States

The University of Tennessee Medical Center
Knoxville, Tennessee, United States

Rio Grande Urology
El Paso, Texas, United States

The Urology Place
San Antonio, Texas, United States

Danville Urologic Clinic
Danville, Virginia, United States

Potomac Urology
Fairfax, Virginia, United States

Virginia Urology
Richmond, Virginia, United States

Valley Health Urology
Winchester, Virginia, United States

Contacts

Jayson Garmizo
310-912-2230
jayson.garmizo@immunitybio.com

Not Provided

ImmunityBio, Inc.
NCT Number
MeSH Terms
Non-Muscle Invasive Bladder Neoplasms